23 results on '"Kotha, Jayaprakash"'
Search Results
2. Abstract 20955: Synergistic Effects of Rivaroxaban With Direct-Acting Anti-Platelet Agents on Platelet Reactivity and Thrombin Generation
3. Abstract 1308: Development and validation of a flow cytometric assay for measuring glycoprotein A repetitions predominant protein GARP target engagement by ABBV-151
4. Validation of a Modified Anti-FXa Assay on STA-Compact Analyzer for Measuring FXa Inhibitor Levels in the Presence of Andexanet Alfa
5. Tetraspanins and vascular functions
6. Tetraspanin CD9 regulates β1 integrin activation and enhances cell motility to fibronectin via a PI-3 kinase-dependent pathway
7. CRT-200.52 Dynamic Regulation of Aggregate Formation and Stability in Response to Platelet Inhibition Via GP 2b-3a vs. P2Y12
8. Parstatin Mediates Platelet Activation That Is Unaffected By PAR Antagonism
9. Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model
10. Impact of D-Dimer Assays Performed at Local Labs Vs. Central Laboratory in the Evaluation of Apex Trial Outcomes
11. Abstract 18218: In Vitro Characterization of Andexanet Alfa (PRT064445), a Specific fXa Inhibitor Antidote versus Aripazine (PER977), a Non-specific Reversal Agent
12. Tetraspanin CD9 modulates human lymphoma cellular proliferation via histone deacetylase activity
13. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact
14. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes
15. The Utility of Platelet and Coagulation Testing of Antithrombotics: Fusing Science with Patient Care
16. Tetraspanin CD9 Promotes the Invasive Phenotype of Human Fibrosarcoma Cells via Upregulation of Matrix Metalloproteinase-9
17. PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL
18. Functional relevance of tetraspanin CD9 in vascular smooth muscle cell injury phenotypes: A novel target for the prevention of neointimal hyperplasia
19. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
20. Absence of Antibody to HTLV-1 in Sera of Asian Indian Patients with Systemic Autoimmune Rheumatic Diseases
21. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes
22. Molecular Mechanism of Tetraspanin CD9 Mediated Cell Motility
23. Tetraspanin CD9 regulates beta 1 integrin activation and enhances cell motility to fibronectin via a PI-3 kinase-dependent pathway.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.